




# KARNATAKA REGISTERED PHARMACISTS ASSOCIATION<sup>®</sup>

# CH 51, 6th Main, 5th Cross, 1st Floor, Above Sri Krishna Bakery, Saraswathipuram, Mysuru-570009.

Ph: 9738366942 Web : [www.krpaindia.com](http://www.krpaindia.com) Email : [krpaindia@gmail.com](mailto:krpaindia@gmail.com)

## CONTENT

- 1.ACS: a challenging condition by - **Mr. Sunil S Chiplunkar**
- 2.OMICRON – THE RULER OF 2022? By - **Mr. Ravinandan A P & Dr. Prizvan Lawrence D Souza**
- 3.ಇದುವೇ ಬೇಡಿಕೆ ಬರಲಿದೆ ಈ ನವ ವರ್ಷ by - **Dr. Rekha Shetty**
- 4.Events and Activities
- 5.Inspirational Pharmacist - **Ms. Pranathi Reddy & Dr. Nagashree K S**
- 6.Quiz



## EDITORIAL TEAM

Mrs. Shilpa Palaksha  
 Dr. Chandni Saha  
 Dr. Sri Harsha Chalasani  
 Mr. Balaji S  
 Mr. Ravinandan A P  
 Dr. Annegowda H V  
 Ms. Nayana P Kunderi  
 Dr. Jehath M Syed  
 Dr. Nagashree K S  
 Dr. Ravina Ravi  
 Ms. Shifa Taj  
 Ms. Priya J Aradhya

**SERVE THE  
 NATION**

**Let us together serve the Nation.  
 If each citizen takes one step Forward,  
 the country takes 130 crore steps Forward.**



# ACS

## A CHALLENGING CONDITION

Market data points to increasing heart and blood vessel diseases in India, due to genetic reasons, unhealthy eating habits, chemical abuse, sedentary lifestyle and stress. As per AIOCD AWACS Dec 2021 market report, the Indian pharmaceutical market has annual sales of Rs. 1,67,232 crores and value growth of 14.90%. In this Indian pharmaceutical retail market, the cardiac care pharmaceutical segment is Rs. 21,688 crores with a growth of

9.00% (MAT Dec 2021 figures).

ACS refers to acute coronary syndrome; it refers to various conditions associated with sudden reduced blood supply to the heart. Myocardial infarction (MI) or heart attack that occurs due to cell death in the heart leads to reduced blood supply to the heart. There are other conditions - without heart cell death - that cause ACS.

The coronary artery is the first branch of aorta or main artery. Aorta arises from the left ventricle. The coronary artery and its branches, supply oxygenated blood to heart cells. If there is a block in the coronary artery and its branches due to deposition of cholesterol or increased levels of homocysteine that damages inner lining of blood vessels, there is reduced blood supply to heart musculature. The myocardium or heart muscles experience insufficient supply of oxygenated blood and this causes stress on heart since there is a residual demand to pump out adequate blood from the heart to all parts of the body. During intense gym exercise if blood vessels supplying blood to heart, are not adequately functioning it can cause sudden death heart attack or cardiac arrest as seen in some gym death cases. Cardiac arrest is related to abnormal electrical conducting system of the heart. Hence, the health of coronary artery is crucial to heart health.

The most common symptom of acute coronary syndrome (ACS) is chest pain. It is often accompanied with tightness in chest, breathing difficulty (dyspnea), a sense of a great load on the chest, dizziness, fainting, light headedness, sudden heavy sweating (diaphoresis), nausea, vomiting, indigestion, and a radiating pain to the arms (particularly left upper arm), back, neck and jaw.

### STEMI in Indian ACS patients

In the Indian scenario, an important observational study outcome is that Indian patients have higher incidence of STEMI: ST Elevation Myocardial Infarction. What this implies is that in the ECG (electrocardiogram) the ST segment is elevated or raised and there is cell death in the myocardial tissue (portions of the heart muscle are dead in the STEMI patient). STEMI is the most severe form of heart attack or MI (myocardial infarction). STEMI heart attack patients require immediate hospitalization, as the blockage in coronary artery is serious. A surprising US North Carolina study is that inpatients - people hospitalized for some other reason and who suffer STEMI heart attack in the hospital are 10 times more likely to die than the STEMI heart attack victim outside the hospital. This indicates a sick older person cannot cope easily with a STEMI heart attack that primarily occurs due to complete coronary artery blockade, STEMI heart attack is also called 'widowmaker'. The STEMI heart attack mainly affects the heart's lower chambers (ventricles). STEMI heart attack is a painful and dangerous form of ACS condition.

In India, cardiovascular (heart + blood vessel) disease is responsible for about 27% of all deaths. Researchers have seen more mortality and morbidity due to CVD (cardiovascular disease) in the lower socioeconomic group, probably due to lack of understanding of morbid diseases, alcoholism, tobacco usage, and poor control of diabetes, dyslipidemia and hypertension. STEMI heart attacks are also having higher incidence in lower socioeconomic groups. Just as we have STEMI there is also non ST elevated MI (NSTEMI or NSTEMI ACS).

### Pharmacists and ACS

Pharmacists are frontline healthcare workers in the healthcare ecosystem. Their counsel while providing medicines and nutraceuticals to improve heart health in vulnerable people and patients with prescriptions shall go a long way to improve healthcare outcomes. Understanding presentations of ACS, and about cardiac medicines plus other healthcare interventions in these cases is essential to pharmacists as 27% of deaths in India are due to ACS. From ACS related medications point of view, aspirin prescribed often to the aged can cause life threatening GI haemorrhage as an ADR. There is also the phenomenon of drug tolerance to blood thinning agents like aspirin and clopidogrel. These drugs prevent platelet aggregation. Further, understanding the concept of haemodynamic equation:  $BP = CO \times PVR$  where BP is blood pressure, CO is cardiac output and PVR is peripheral vascular resistance is very useful to understand the functioning of cardiovascular system and pathology of cardiovascular disease including ACS.

**Mr. Sunil S Chiplunkar**

M Pharm (Pharmacology) MBA (Marketing) PGDHRM (PhD)  
VP - Business Development, Group Pharmaceuticals, Bangalore,  
Email: 1969sunilchiplunkar@gmail.com



Specially formulated  
toothpaste for kidz



**Rediflor® kidz**

Only toothpaste with  
**10% xylitol**

**Stronger  
Milk Teeth**



Musk Melon



Bubble Gum



Natural Orange




Green Apple



# OMICRON

## THE RULER OF 2022?



With the world being vaccinated and finding new hope after the second wave, comes a new variant of concern OMICRON (B.1.1.529), which was first identified in South Africa during the second week of November 2021. The World Health Organization's (WHO) Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) on 26th November 2021 decided to make Omicron a variant of concern based on the evidence and several mutations seen. \*TAG-VE is an independent group that consists of experts who periodically monitor and evaluate the evolution of SARS-CoV-2 and assess if any specific mutations or combinations of mutations alter the behaviour of the virus. Omicron is a highly divergent variant with a large number of mutations, including 26 to 32 in the spike protein, some of which are concerning and may be associated with immune escape potential and higher transmissibility. The risk associated with the variant is still under research but preliminary evidence suggests that it has a high transmission rate and can also escape the human immune system leading to reinfection when compared with other variants. Data on hospitalization remain limited but most of the cases were found to be asymptomatic or had mild symptoms. In South Africa, an 82% increase in hospital admissions was seen from 28th November 2021 to 4th December 2021. Since the transmission is very high it can increase the number of hospitalizations and can put a burden on health care systems leading to more deaths. As of 18th December 2021, the omicron variant in India had crossed the 100-mark with most of the cases coming from Maharashtra, followed by Delhi and Rajasthan. Only one death has been recorded so far in the United Kingdom.

SARS-CoV-2 infection is generally diagnosed by using molecular tests (NAAT or PCR) or antigen-detection assays. As per the sequence analysts of the US FDA, PCR tests that include multiple gene targets can be used to detect the Omicron variant. Less data is currently available to assess the mutations present on the Omicron variant that may result in reduced protection from vaccine-derived immunity. Evaluation of virulence and the ability to escape the immune response can be assessed by animal studies. Neutralization activity of plasma collected from vaccinated and previously infected individuals could be helpful in testing against Omicron. Sharing of reagents and knowledge with respect to laboratory research can help in the critical evaluation of the Omicron variant.

Another key clinical information is the effectiveness of current vaccines on the Omicron variant. These studies will help to determine the degree to which previous vaccination or infection can protect against infection, mild disease or severe disease caused by the variant. Vaccine effectiveness studies can be quickly conducted in places with a higher incidence of the Omicron variant to provide a first indicator of clinical vaccine performance. Currently WHO has suggested the use of Interleukin-6 Receptor blockers and corticosteroids for the treatment of infected individuals. Researches for the use of other therapeutic agents are still being carried out in order to understand the effectiveness on this variant. Preliminary data published also suggests the use of monoclonal antibodies (sotrovimab, Bamlanivimab, Etesevimab and REGEN-COV) developed against SARS-CoV-2 have decreased neutralization against Omicron.

### READINESS OF HEALTH CARE SYSTEM

Health care must be prepared for the expected third wave and associated pressure. COVID-19 Essential Supplies Forecasting Tool needs to be used for estimating the number of PPE, diagnostics, oxygen and therapeutics. Training of workforce with standardized materials should be continued.

### PREVENTION GUIDELINES TO CONTROL THE TRANSMISSION

1. Implementation of Enhanced Surveillance by conducting large-scale sampling and testing of the population for identifying the specimens with S-gene target failures (SGTFs). Containment zones and restrictions within these areas can reduce the spread of this variant.
2. Airport Surveillance – Suspending or reducing the number of flights from highly containment countries can help in the control of this strain. Immigrants flying from one country to another should be completely vaccinated and require a previously taken RT-PCR (Not more than 72 hours). They must also undergo voluntary testing at the arriving international airports and follow home or institutional quarantine for 7 days, with another RT-PCR test. All positive samples must be sent for sequencing.
3. Prioritization of Laboratory studies for Vaccines and Therapeutic Agents – Laboratory studies must be prioritised in order to evaluate and assess the ability of vaccines and convalescent sera to neutralize the Omicron variant, the susceptibility of the variant to the treatments and the ability of vaccine-induced immunity to protect against illness and death. Vaccines play a major role in limiting the spread of SARS-CoV-2 and minimizing the severity of the disease. Hence, a low vaccination drive can increase the chance of transmission and death.
4. Prevention Strategies – Continuation of the vaccination drive for every individual nation or worldwide. Wearing masks, social distancing, prohibiting social gatherings, quarantine and isolation, handwashing and sanitizing, consuming immunity booster foods and supplements, and improved ventilation should be followed.



**Dr. Prizvan Lawrence D Souza,**

Pharm.D  
Assistant Professor,  
Department of Pharmacy Practice,  
Sree Siddaganga College of Pharmacy,  
Tumakuru, Karnataka, India



**Mr. Ravinandan A P,**

M. Pharm, MBA, FSASS, (Ph.D.)  
Assistant Professor, Clinical Pharmacist & Research Scholar  
Department of Pharmacy Practice  
Sree Siddaganga College of Pharmacy  
In Collaboration with Siddaganga Hospital & Research Centre  
BH Road, Tumkur, Karnataka

# ಇದುವೇ ಬೇಡಿಕೆ ಬರಲಿದೆ ಈ ನವ ವರ್ಷ

ಹೋದ ವರ್ಷದ ಕ್ಯಾಲೆಂಡರ್ ಎಸೆಯಲು ತೆಗೆದಿಟ್ಟ  
ಹೊಸತನ್ನು ಮೊಳೆ ಯಲ್ಲಿ ನೇತಾಡಿಸಿ ಬಿಟ್ಟ  
ಫ್ಯಾನ್ ತಿರುಗುತ್ತಿತ್ತು ಜೋರಾಗಿ ಮಾಡಿ ಶಬ್ದ ಗರ್ - ಗರ್ಜನೆ  
ಹಳತು ಕ್ಯಾಲೆಂಡರ್ನ ಪುಟಗಳು ತಿರುಗಿತು ಸರ್ - ಸರ್ಜನೆ  
ಅದರ ಪುಟಗಳನ್ನು ನೋಡಿ ನೆನಪಿನ ಸುರಿಮಳೆ ಸು ರಿಯಿತು ಮೆಲ್ಲ -ಮೆಲ್ಲನೆ  
ಕಳೆದ ವರ್ಷದ ಮುಂಚಿನ ವರ್ಷ  
ಹೋರಾಡಲು ಕೊರೊನಾ ಎಂಬುವ ಮಹಿಷಾಸುರನ ವಿರುದ್ಧ  
ನಾವೆಲ್ಲರೂ ಇದ್ದೆವು ಸಿದ್ಧ  
ಆರೇಳು ತಿಂಗಳಿಂದ ಮನೆಯಲ್ಲಿ ಇದ್ದು  
ಯುದ್ಧ ಗೈದೆವು ಕೊರೊನದ ವಿರುದ್ಧ ಮಾಡದೆ ಸದ್ದು  
ಮುಖಕ್ಕೆ ಮಾಸ್ಕ ಧರಿಸಿ  
ಆರು ಅಡಿ ಒಬ್ಬರಿಂದ ಇನ್ನೊಬ್ಬರು ದೂರ ಸರಿಸಿ

ಕಳೆದ ವರ್ಷ ಈ ಮಹಿಷಾಸುರ ಧರಿಸಿದ ಯಮರಾಜನ ರೂಪ  
ಇವನ ಈ ರೂಪ ,ಮನೆಯಿಂದ ಹೊರ ಕಾಲಿಡಲು ಮಾಡುತ್ತೇ ಅನೇಕ ನೇಪ  
ಅಂದು ಖುಷಿಯಿಂದ ನರ್ತಿಸುವನು ಇವನು ನೋಡಿ ನಮ್ಮ ಹೋರಳಾಟ  
ಯುದ್ಧ ಗೆದ್ದಿರುವ ಜಂಬ ತಲೆತೋರುತ್ತಿದೆ ಇವನ ಹಾರಾಟ  
ನಮ್ಮ ಸಕಲ ಪ್ರಯತ್ನಕ್ಕೆ ಬಿತ್ತು ನೀರು  
ಹರಡುತ್ತಿರುವನು ತನ್ನ ಅಸ್ತಿತ್ವದ ಬೇರು  
ದೇವರೇ ,ನಿಮ್ಮ ಬದಲಿಗೆ ಇವನನ್ನು ಸ್ಮರಿಸಿ ಸುರುವಾಗುತ್ತೇ ನಮ್ಮ ದಿನ  
ದಿನ ಸವಿದಂತ್ತೆ ಮುದುಡುತ್ತದೆ ನಮ್ಮ ಮನ  
ಕನಸು ಕಂಡೆವು ಸ್ವಚಂದದಿಂದ ಉಸಿರಾಡಲು,  
ನಮ್ಮ ಸಿದ್ಧತೆ ವಿಫಲಿಸಿತು ಇವನ ವಿರುದ್ಧ ಹೋರಾಡಲು  
ಈಗ ಇನ್ನೊಂದು ಮುಖವಾಡ ಧರಿಸಿ ಅವನು ನಗುತ್ತಿರುವನು ಹಾರಿ -ಹಾರಿ  
ಮಾಡಿ ನಮ್ಮ ಹೃದಯವನ್ನು ಚೀರಿ- ಚೀರಿ  
ದೇವರೇ, ಕಂಡೆವು ಇವನನ್ನು ಕೊಲ್ಲಲು ನಿಮ್ಮ ಸಹಾಯದ ವಿನಃ ನಮಿಂದ ಅಸಾಧ್ಯ  
ಬೇಡುವೆವು ಬಾರಿಸಿ ವಿವಿಧ ವಾದ್ಯ  
ನಿನ್ನ ಅಸಾಮಾನ್ಯ ಬುದ್ಧಿಯಿಂದ ಚಕ್ರವ್ಯೂಹ ರಚಿಸಿ ,  
ಕೊನೆಗೊಳಿಸು ಇವನ ಅಸ್ತಿತ್ವ ಇವನ್ನನು ವಂಚಿಸಿ  
ನಿನ್ನ ಶ್ರದ್ಧೆ,ಭಕ್ತಿ ಹೀಗೆಯೇ ನೆಲೆಯಲಿ ನಮ್ಮ ಮನದಲ್ಲೆ ,  
ನೀನು ಸುರಿಸುತ್ತಿರು ನಿಮ್ಮ ಆಶೀರ್ವಾದ ನಮ್ಮೆಲ್ಲರ ಜೀವನದಲ್ಲೆ  
ಮಾಡು ಇಡೀ ಜಗತ್ತನ್ನೇ ಮುಕ್ತಾಯ ಈ ಕೊರೊನಾದ ಶಾಪದಿಂದ  
ಇದುವೇ ಬೇಡಿಕೆ ಬರಲಿದೆ ಈ ನವ ವರ್ಷ ನಮೆಲ್ಲರ ಮನದಿಂದ  
ಇದುವೇ ಬೇಡಿಕೆ ಬರಲಿದೆ ಈ ನವ ವರ್ಷ ನಮೆಲ್ಲರ ಮನದಿಂದ



**Dr. Rekha K Shetty** MBBS  
Medical Advisor

## Comprehensive Immune Nutrition

# Mulmina<sup>®</sup>

Say hello to health...

Clinically Proven

Immune Booster, Antioxidant and Stress Reliever

**Low GL of 3.64**

Blood sugar does not peak abnormally and glycemic variability is minimised with Low GL Score

ORAC\*  
VALUE  
**5668/PACK**

ORAC\*  
VALUE  
**5400/PACK**



**Immune booster & Antioxidant to meet the requirement of your patients**

- Aseptic packing
- No Preservatives
- Ready to Drink

*Meets recommended daily requirement of antioxidants*

USDA Recommends 3000 - 5000 ORAC Units/Day\*

<https://agreesearchmag.ars.usda.gov/1999/feb/aging>

ORAC: Oxygen Radical Absorbance Ca



**JUGGAT PHARMA**

(Division of Jagdale Industries Pvt. Ltd.)  
No.782, 15th Cross, 1st Phase,  
JP Nagar, Bangalore - 560 078

Toll free No: 1800 425 6939  
e-mail: info@jagdale.com  
visit us at: www.jagdale.com

# EVENTS AND ACTIVITIES

A joint meeting was held on 24th January at Karnataka State Pharmacy Council(KSPC), Bangalore. Executive members of Karnataka Pharma Retailers and Distributors organisation, Karnataka Registered Pharmacist Association (KRPA) President Dr. Kaushik Devaraju and director Dr. Balamurlidara Gowda, Associate professor, JSSCPM, trustees of Karnataka Pharmacy Council Registered Pharmacist welfare Trust(KPCRPT) and President KSPC, Mr. D A Gundurao, KSPC Registrar Prof B G Shivananda, Mr Y. Veeranarayana Gowda, EC Member KSPC were the members who were present in the meeting.

## The main Agenda of the meeting was:

1. To discuss and present the request for increasing the Compensation money provided to pharmacist family members from 2 lakhs to 5 lakhs under the welfare scheme.
  2. Felicitating pharmacist on World Pharmacist Day every year as per the requisition of many pharmacy associations.
  3. To discuss on the longstanding KSPC election. Challenges and opportunities for conducting the same.
- All the members discussed the matters in detail. The discussion was equally supported by others members who were present namely, Dr. S. Ramachandra Setty, Principal of Government College of Pharmacy, Shri. Sunil S Chiplunkar Mr. Sunil Chiplunkar, VP-Business Development, Group Pharmaceuticals and KRPA Director. Also equally participated were KPRDO vice president M.K. Mayana, Administration Secretary K. Harish Kumar and Pharmacist Mr. Vivek Kumar.



## Members of KRPA participated as Resources Persons

KRPA has always been motivating the pharmacist at all levels. Members of KRPA, has participated as resource person at Training of Government Pharmacist conducted by District Training centre of Hassan on 4th of January. Dr. Kaushik Devaraju, President KRPA and Director Mr. Sunil Chiplunkar were invited to share the expertise in the field of Pharmacy.


It was a 2 day session conducted in batches of pharmacist. Both the resource person were well appreciated and received by the pharmacist.



## Mr. Sunil Chiplunkar being felicitated after his interesting talk




## Dr. Kaushik Devaraju, with Pharmacist after his session



# ATRIMED

## Pioneering in COVID-19 Research

### Experts in Phyto-Biotechnology



## Introducing A Research Based Formula To Fight The Pandemic



# Vyvuz

Capsules

A product of  
Phyto-Research



Centella asiatica



Andrographis paniculata



Withania somnifera

### Exclusive Range For Respiratory Care

**Rhinorm**  
Capsule

**Spazex**  
Syrup & Capsule

**Berykof**  
Syrup

ATRIMED



No. 29-30, Prestige Meridian, 14th Floor, Tower 2, MG Road, Bengaluru - 560001.

Ph: +91 80 41123727, +91 80 43725015 | Email: info@atrimed.com

www.atrimed.com



Dayananda Sagar University Bengaluru  
College of Pharmaceutical Sciences

Webinar

Topic **Presents**

**ROLE OF PHARMACOLOGY IN PHARMACEUTICAL MARKETING AND MANAGEMENT**

<https://event.webinarjam.com/channel/DayanandSagarPharmac>

**Mr. Sunil S Chiplunkar**  
M Pharm (Pharmacology) MBA (Marketing) PGDHRM (PhD)  
VP - Business Development, Group Pharmaceuticals

**06.12.2021 Monday** **TIME:- 11.30 AM TO 12:30 PM**

**ORGANISING TEAM**

**Convener:** Dr Pushpa Sarkar MBBS MD, Dean, School of Allied Health Sciences, Dayananda Sagar University  
**Co Convener:** Dr. V. Murugan M.Pharm., Ph.D. Principal - College of Pharmaceutical Sciences, DSU  
**Organizing Secretary:** Dr. Geetha K M, M.Pharm, Ph.D., Professor & Head, Department of Pharmacology, COPS, DSU

Group Pharmaceuticals Ltd healthy smiles matter SHY-NM KARNATAKA REGISTERED PHARMACEUTICAL ASSOCIATION

E certificate will be despatched - stay till end of webinar.

## Online education contribution by KRPA

College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru invited Mr. Sunil Chiplunkar, VP-Business Development, Group Pharmaceuticals and KRPA Director, to share his expertise of Pharma marketing at an webinar “ **Role of Pharmacology in Pharmaceutical Marketing and Mangement**”. Conducted on 6th December 2021. The talk was appreciated especially the budding pharmacist participants.

The event was supported by KRPA and Group Pharmaceuticals

n another webinar supported by KRPA and collaborated by College of Pharmaceutical Sciences Dayananda Sagar University was conducted on 7th December 2021.

The topic of the webinar was “Regulatory Affairs-The perspectives and career opportunities”. The speaker of the webinar was Dr. Sanil Kumar, Associate Vice President- Risk & Compliance, Accenture, Bengaluru. He added his practical experiences and his experience to enlighten the pharmacy students.

Dayananda Sagar University Bengaluru  
College of Pharmaceutical Sciences

Webinar

Topic **Presents**

**“REGULATORY AFFAIRS - THE PERSPECTIVES AND CAREER OPPORTUNITIES”**

<https://event.webinarjam.com/channel/COPSDSURegulatory>

**Dr. Sanil Kumar**  
M. Pharm., Ph. D., Associate Vice President – Risk & Compliance, Accenture, Bengaluru

**07.12.2021 Tuesday** **TIME:- 11.30 AM TO 12:30 PM**

**ORGANISING TEAM**

**Convener:** Dr Pushpa Sarkar MBBS MD, Dean, School of Allied Health Sciences, Dayananda Sagar University  
**Co Convener:** Dr. V. Murugan M.Pharm., Ph.D. Principal - College of Pharmaceutical Sciences, DSU  
**Organizing Secretary:** Dr. B. Wilson, M. Pharm, Ph. D., Professor & Head, Department of Pharmaceutics, COPS, DSU

Group Pharmaceuticals Ltd healthy smiles matter SHY-NM KARNATAKA REGISTERED PHARMACEUTICAL ASSOCIATION

E certificate will be despatched - stay till end of webinar.

Dayananda Sagar University (Bengaluru)  
College of Pharmaceutical Sciences

**Presents**

Topic  
**CAREER OPTIONS IN PHARMACY**

<https://event.webinarjam.com/channel/Careerspharmacy>

**Mr. B.R.RACHU BABU**  
M Pharm MBA  
Head Operation Excellence, Bluefish Pharmaceuticals

**10.12.2021 Friday**      **TIME:-**  
**11.30 AM TO 12:30 PM**

**ORGANISING TEAM**

**Convener:** Dr Pushpa Sarkar MBBS MD, Dean, School of Allied Health Sciences, Dayananda Sagar University

**Co Convener:** Dr. V. Murugan M.Pharm., Ph.D. Principal - College of Pharmaceutical Sciences, DSU

**Organizing Secretary:** Dr.Kalpana Divekar, M.Pharm, Ph.D., Professor, Department of Pharmachemistry, COPS, DSU

Group Pharmaceuticals Ltd healthy smiles matter    SHY-NM    KARANTAKA REGISTERED PHARMACIST ASSOCIATION

E certificate will be despatched - stay till end of webinar.

With the same collaboration another webinar was conducted on the topic “ Career Options IN Pharmacy”. The experienced speaker was Mr. B.R Rachu Babu, Head Operation Excellence, Bluefish Pharmaceuticals. The webinar was conducted on 19th December 2021. It was very interesting especially the outgoing pharmacy students were enriched with the available career pathways.

Webinar on Role of botanicals in dental care was conducted on 29th January 2022. The Speaker for the event was Dr. Meenakshi S, Assistant Professor, Department of Prosthodontics, JSSDC, Mysuru. Herbal application is the new trend in healthcare, this is what Dr. Meenakshi emphasized and explained its application in dental care. The event was jointly organised by PA College of Pharmacy, Mangalore, Society of Ethnopharmacology, Mangalore, Group Pharmaceuticals and KRPA.

PA COLLEGE OF PHARMACY MANGALORE    SOCIETY FOR ETHNOPHARMACOLOGY MANGALORE

**Present**

Topic  
**Role of botanicals in dental care**

<https://event.webinarjam.com/channel/PACPrMeenakshi>

**Dr. Meenakshi S**  
BDS MDS PhD, Asst. Prof., Department of Prosthodontics, JSS Dental College, JSSAHER, Mysuru

**29.01.2022 Saturday**      **TIME:-**  
**10:00 AM TO 11:00 AM**

**PROGRAM DETAILS**

**Welcome address:** Dr. Saleemulla Khan M Pharm PhD Principal PA College of Pharmacy, Mangalore

**Onboarding talk:** Mr. Sunil S Chiplunkar M Pharm (Pharmacology) MBA (Marketing) PGDHRM, (PhD) VP - Business Development, Group Pharmaceuticals, Bangalore

**Vote of thanks:** Dr. Kaushik Devaraju M Pharm PhD, President, KRPA Mysuru

Group Pharmaceuticals Ltd healthy smiles matter    SHY-NM    KARANTAKA REGISTERED PHARMACIST ASSOCIATION

E certificate will be despatched - stay till end of webinar.

# KRPA WISHES THE NEW ACHIEVERS

# Best wishes

Students from Sharada College of Pharmacy, Mysuru and Adichunchanagiri College of Pharmacy B G Nagara. Students have excelled in the B.Pharm Examinations conducted by Rajiv Gandhi University of Health University.



## Sarada Vilas College of Pharmacy

Krishna Murthy Puram, Mysuru- 570004

Approved by PCI, New Delhi, Govt. of Karnataka, Approved by Rajiv Gandhi University of Health Sciences, Karnataka



Estd. 1992

# Congratulations

To the following students for securing ranks in the RGUHS exams Nov. 2021



**Pavitha M**  
1st Rank  
5th Pharm. D.



**Kiran M**  
6th Rank  
2nd B. Pharm.



**Salman M**  
10th Rank  
4th B. Pharm.



**Shifa Taj**  
10th Rank  
5th Pharm. D.

Management, Principal, Staff and Students of Sarada Vilas College of Pharmacy

[www.svcop.org](http://www.svcop.org)

[mysoresvcop@gmail.com](mailto:mysoresvcop@gmail.com)

**9663373701 0821-2488612**

### Courses

- Doctor of Pharmacy - 6 years
- Bachelor of Pharmacy - 4 years
- Diploma in pharmacy - 2 years
- Master of Pharmacy - 2 years
- Doctorate of Philosophy (Ph.D.)



## Sri Adichunchanagiri College of Pharmacy

B G Nagara-571448



# Congratulations

RGUHS Exam November- 2021  
Results/Ranks/Toppers



**PHARMA D IV YEAR -100% RESULTS**  
a) **Mr. Ankith 8th Rank - 86%**  
b) Total Subjects Ranks - 48 No's



**PHARM D V YEAR-100% RESULTS**  
Total Subject Ranks - 57 No's



**B Pharm -Sem. VIII 98% Results**  
Total Subjects Ranks-39 No's

*We Thank all stakeholders for their constant support*

# INSPIRATIONAL PHARMACIST

**DR. SUBHASH C. MANDAL**



Dr. Subhash C. Mandal, renowned and outstanding pharmacist in Indian Pharmaceutical Sector. He is currently the Vice President & chairman, Regulatory Affairs Division, Indian Pharmaceutical Association. A gem in the eyes of many and a foundation for many successes. He fits the definition of what leadership means perfectly. He is one of the most influential people in India.

Dr. Subhash C. Mandal started his career as a teacher and has experience in industry and regulatory affairs for more than 20 years. Dr. Mandal has contributed 12 book chapters published by the reputed publishers like American Chemical Society (ACS). He has 58 publications in his credit in different international journals.

Dr. Subhash C. Mandal always believed in – “If your actions inspire others to dream more, learn more, do more and become more, you are a leader.” He always maintained authentic leadership.

He served in several important committees and task forces formed by different Govt. and International agencies. He also served as a member of Editorial Board and reviewer of several Journals of international repute. Dr. Subhash C. Mandal is a founder co-coordinator of Drug Information Centre (DIC) on behalf of IPA, Bengal Branch and continuing till date and publishing a weekly Bulletin-Drug Information Bulletin (Electronic) as the Editor for more than 14 years on behalf of IPA, Bengal Branch, which is not only popular in India but throughout the globe.

Dr. Subhash C. Mandal recently received Eminent Pharmacy Award (the highest Award of IPA). He is also currently serving as the President of ISPOR-India West Bengal Chapter. He also participated in the “International Conference on “Frontiers in Pharmaceutical Science & Research” at Raipur, Chhattisgarh jointly organized by Columbia Institute of Pharmacy and Society for Ethnopharmacology, India during 11th -12th October 2014 and made a presentation on “Impact of Pharmacoeconomics in health care sector: regulatory perspective.”

Dr. Subhash C. Mandal, not only as a professor but also as a person is one of the most dedicated, enjoyable and hardworking person to work with. He is willing to go above and beyond what is called on to do well for those around him. Every idea shared and every opportunity seized by him has helped in achieving such great heights in the field of Pharmacy.



**Ms. Pranathi Reddy,**  
IV Pharm D  
JSS College of Pharmacy,  
Mysuru-15.



**Dr. Nagashree.K.S.**  
Lecturer  
Department of Pharmacology  
JSS College of Pharmacy,  
Mysuru-15.



Advertise  
**HERE**

**PROMOTE  
AND BOOSTUP  
YOUR BUSINESS  
HERE**



# RULES

1. Correct answers will be rewarded 1 point each (10 marks)
2. Answer of the quiz will be evaluated by panel of judges and their decision is final. (Max mark:10)
3. Those who get the highest marks, their photo will be published in our next bulletin and also a cash prize of Rs.500/- will be rewarded to them
4. The answer must be sent within 20<sup>th</sup> February 2022 to this E Mail ID- krpaindia@gmail.com
5. A confirmation mail will be sent to you on receiving your e-mail.

1. Which drug(s) commonly produces 'Red Man Syndrome'?

- a. Ciprofloxacin
- b. Vancomycin
- c. Amphotericin B
- d. All of the above

2. Reason for pungency from chillies is due to

- a. Carotene
- b. Capsanthin
- c. Capsaicin
- d. None of the above

3. Neurocysticercosis is a \_\_\_\_\_

- a. Parasitic infection
- b. Affects central nervous system
- c. Managed by Albendazole
- d. All of the above

4. Pink eyes are nothing but

- a. Conjunctivitis
- b. Endophthalmitis.
- c. Cellulitis.
- d. None of the above

5. Approximately how much TPN is required for adults per day?

- a. 1 litre
- b. 3 litres
- c. 0.5 litre
- d. 2 litres

6. Drugs acts on RNA polymerase activity is

- a. Favipiravir
- b. Molnupiravir
- c. Both a and b
- d. None of the above

7. Kernicterus is \_\_\_\_\_

- a. Brain damage
- b. Increases bilirubin
- c. Due to sulphanilamide
- d. All of the above

8. Patients with which of the following diseases are managed with vitamin B-12 injection?

- a. Pernicious anaemia
- b. Megaloblastic anaemia
- c. Thalassemia
- d. None of the above

9. Government opium factory is located at

- a. Bangalore
- b. New Delhi
- c. Chennai
- d. Srinagar

10. Treatment option(s) for hyperkalaemia

- 
- a. Calcium
  - b. Insulin
  - c. Furosemide
  - d. All of the above



*Congratulations*

*to the winner of Twenty Second Edition*

KRPA Quiz Competition

**Dr. Mohammad Aqil N B**

Clinical Pharmacist,  
KMC Hospital, Mangaluru



Prize Money is Sponsored by  
Group Pharmaceuticals Ltd

healthy smiles matt



# DISCLAIMER

The Newsletter intends to provide updated and reliable information on medicines and other related issues in an attempt to equip healthcare professionals to take informed decision in recommending medicines to the patients. However, they are encouraged to validate the contents. Neither the people associated with the publication of the Newsletter nor the organization shall be liable for any damage incurred as a result of use of the contents of this publication. The brand names of medicines, if mentioned, are for illustration only and the newsletter does not endorse them.

Send your Articles, Suggestions, or Comments to  
**krpaindia@gmail.com**  
for the overall improvement of  
KRPA Monthly Bulletin

**For Business Advertisements**  
Contact

**Kaushik Devaraju**  
+ 91 97383 66942

**Sanjeev Kumar B N**  
+91 87478 44080

Are you a pharmacist yearning to EXPAND your network and explore the world of pharmacy? It's just one click away.

Scan QR Code to become a member of KRPA and enjoy the benefits.

